Octagon Capital Advisors LP / 260
Octagon Capital Advisors LP’s Centessa Pharmaceuticals PLC Position
Does Octagon Capital Advisors LP own Centessa Pharmaceuticals PLC (260)? Yes — 750.0K shares worth $30M (+3.30% of its 13F portfolio) as of Q1 2026.
Position Value
$30M
Q1 2026
Shares
750.0K
% of Portfolio
+3.30%
Quarters Held
13
currently held
Position History 260
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 750.0K | $30M | +3.30% |
| Q4 2025 | 750.0K | $19M | +2.28% |
| Q3 2025 | 830.0K | $20M | +3.05% |
| Q2 2025 | 1.03M | $14M | +2.97% |
| Q1 2025 | 1.43M | $20M | +3.97% |
| Q4 2024 | 1.99M | $33M | +5.49% |
| Q3 2024 | 2.01M | $32M | +5.00% |
| Q2 2024 | 2.35M | $21M | +3.33% |
| Q1 2024 | 2.06M | $23M | +2.79% |
| Q4 2023 | 2.06M | $16M | +2.62% |
| Q3 2023 | 475.6K | $3M | +0.47% |
| Q2 2023 | 411.9K | $3M | +0.35% |
| Q1 2023 | 396.0K | $2M | +0.22% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of 260.